1. Home
  2. HRTG vs GERN Comparison

HRTG vs GERN Comparison

Compare HRTG & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heritage Insurance Holdings Inc.

HRTG

Heritage Insurance Holdings Inc.

HOLD

Current Price

$21.97

Market Cap

704.5M

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.18

Market Cap

808.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRTG
GERN
Founded
2012
1990
Country
United States
United States
Employees
N/A
258
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
704.5M
808.3M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
HRTG
GERN
Price
$21.97
$1.18
Analyst Decision
Strong Buy
Hold
Analyst Count
2
3
Target Price
$33.50
$2.17
AVG Volume (30 Days)
561.2K
13.1M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
214.43
N/A
EPS
1.19
N/A
Revenue
$847,330,000.00
N/A
Revenue This Year
$7.50
$26.91
Revenue Next Year
$6.74
$43.75
P/E Ratio
$17.83
N/A
Revenue Growth
3.71
N/A
52 Week Low
$16.83
$1.04
52 Week High
$31.98
$2.01

Technical Indicators

Market Signals
Indicator
HRTG
GERN
Relative Strength Index (RSI) 39.38 31.48
Support Level $20.98 $1.05
Resistance Level $24.65 $1.30
Average True Range (ATR) 0.88 0.05
MACD -0.00 -0.00
Stochastic Oscillator 37.16 19.44

Price Performance

Historical Comparison
HRTG
GERN

About HRTG Heritage Insurance Holdings Inc.

Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: